| Year |
Citation |
Score |
| 2010 |
Bence AK, Crooks PA. ChemInform Abstract: Synthesis of L-Indospicine. Cheminform. 33: no-no. DOI: 10.1002/chin.200248191 |
0.451 |
|
| 2009 |
Worthen DR, Bence AK, Stables JP, Crooks PA. In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity. Bioorganic & Medicinal Chemistry Letters. 19: 5012-5. PMID 19632831 DOI: 10.1016/J.Bmcl.2009.07.059 |
0.405 |
|
| 2003 |
Bence AK, Crooks PA. The mechanism of L-canavanine cytotoxicity: arginyl tRNA synthetase as a novel target for anticancer drug discovery. Journal of Enzyme Inhibition and Medicinal Chemistry. 18: 383-94. PMID 14692504 DOI: 10.1080/1475636031000152277 |
0.511 |
|
| 2003 |
Bence AK, Adams VR, Crooks PA. L-Canavanine as a radiosensitization agent for human pancreatic cancer cells. Molecular and Cellular Biochemistry. 244: 37-43. PMID 12701807 DOI: 10.1023/A:1022435202066 |
0.472 |
|
| 2003 |
Bence AK, Worthen DR, Stables JP, Crooks PA. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacology, Biochemistry, and Behavior. 74: 771-5. PMID 12543244 DOI: 10.1016/S0091-3057(02)01079-1 |
0.447 |
|
| 2002 |
Bence AK, Worthen DR, Adams VR, Crooks PA. The antiproliferative and immunotoxic effects of L-canavanine and L-canaline. Anti-Cancer Drugs. 13: 313-20. PMID 11984075 DOI: 10.1097/00001813-200203000-00013 |
0.514 |
|
| 2002 |
Bence AK, Crooks PA. Synthesis of L-indospicine Synthetic Communications. 32: 2075-2082. DOI: 10.1081/Scc-120004860 |
0.487 |
|
| 2001 |
Worthen DR, Gibson DA, Rogers DT, Bence AK, Fu M, Littleton JM, Crooks PA. Endogenous indoles as novel polyamine site ligands at the N-methyl-D-aspartate receptor complex. Brain Research. 890: 343-6. PMID 11164802 DOI: 10.1016/S0006-8993(00)03201-7 |
0.458 |
|
| 2000 |
Bence AK, Rogers DT, Worthen DR, Fu M, Littleton JM, Crooks PA. Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex. Bioorganic & Medicinal Chemistry Letters. 10: 2621-3. PMID 11128637 DOI: 10.1016/S0960-894X(00)00530-8 |
0.454 |
|
| 2000 |
Bence AK, Rogers DT, Worthen DR, Fu M, Littleton JM, Crooks PA. Dapsone analogs as potential polyamine binding site modulators of the N-methyl-D-aspartate receptor complex Drug Development Research. 51: 268-272. DOI: 10.1002/Ddr.8 |
0.465 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2004 |
Bence AK, Mattingly CA, Burke TG, Adams VR. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells. Cancer Chemotherapy and Pharmacology. 54: 354-60. PMID 15197485 DOI: 10.1007/S00280-004-0804-3 |
0.238 |
|
| 2005 |
Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, Smith DA, Koch KM, Stead AG, Mangum S, Bowen CJ, Spector NL, Hsieh S, Adams VR. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Investigational New Drugs. 23: 39-49. PMID 15528979 DOI: 10.1023/B:Drug.0000047104.45929.Ea |
0.218 |
|
| 2002 |
Bence AK, Adams VR. Pegfilgrastim: a new therapy to prevent neutropenic fever. Journal of the American Pharmaceutical Association (Washington,D.C. : 1996). 42: 806-8. PMID 12269716 DOI: 10.1331/108658002764653595 |
0.195 |
|
| 2001 |
Bence AK, Sheehan JB, Adams VR. Antiangiogenesis agents in clinical trials Journal of the American Pharmaceutical Association (Washington,D.C. : 1996). 41: 893-895. PMID 11765116 DOI: 10.1016/S1086-5802(16)31340-7 |
0.188 |
|
| 2008 |
Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 324: 95-102. PMID 17947497 DOI: 10.1124/Jpet.107.127704 |
0.098 |
|
| 2009 |
Shen F, Bailey BJ, Chu S, Bence AK, Xue X, Erickson P, Safa AR, Beck WT, Erickson LC. Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 330: 423-9. PMID 19423841 DOI: 10.1124/jpet.109.153551 |
0.096 |
|
| 2012 |
Calvo E, Dickgreber N, Hynes S, Decker R, Kumm E, Ohnmacht U, Bence A, Wehler T, Sebastian M. 586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer European Journal of Cancer. 48: 179-180. DOI: 10.1016/S0959-8049(12)72383-3 |
0.09 |
|
| 2010 |
Weiss G, Donehower R, Westin E, Bence A, Hynes S, Hurt K. 516 A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer European Journal of Cancer Supplements. 8: 165. DOI: 10.1016/S1359-6349(10)72223-0 |
0.078 |
|
| 2010 |
Marshall M, King C, Barnard D, Diaz H, Barda D, Bence A, Westin E. 194 Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor European Journal of Cancer Supplements. 8: 65. DOI: 10.1016/S1359-6349(10)71899-1 |
0.073 |
|
| 2012 |
Wu W, Bi C, Beckmann R, Foreman R, Wang T, Bence A. 198 Antitumor Effect of Chk1 Inhibitor LY2603618 in Combination with Gemcitabine in SW1990 Pancreas Orthotopic Tumor Model European Journal of Cancer. 48: 60. DOI: 10.1016/S0959-8049(12)71996-2 |
0.059 |
|
| Hide low-probability matches. |